This update is in follow-up to the FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron) on 9/15/2011.
FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)
Mississippi State Department of Health • 570 East Woodrow Wilson Drive • Jackson, MS 39216 • 866-HLTHY4U • web@HealthyMS.com
